The Life Sciences team advised Ouro Medicines on its launch with $120 million in funding. The company was founded by Monograph Capital in partnership with GSK plc. The Series A was co-led by TPG Life Sciences Innovations, NEA, and Norwest Venture Partners, with participation from Monograph Capital, GSK, UPMC Enterprises, Boyu/Zoo Capital, LongRiver Investments, and other unnamed investors. Ouro’s most advanced product candidate is OM336, a BCMA-directed, bispecific T cell engager recently licensed with Goodwin representation from Keymed Biosciences (2162.HK). BCMA is highly expressed across several B cell subtypes that play a role in driving multiple indications where high specificity and potency are needed to achieve near-complete B cell depletion. Behind its lead program, Ouro intends to advance a broad set of discovery programs targeting additional dimensions of B cell biology.
Ouro Medicines is a biotechnology company dedicated to developing immune reset therapeutics for people living with chronic immune-mediated diseases. Ouro's approach is focused on leveraging T cell engagers in B cell mediated diseases to achieve immune resets that create durable remissions without ongoing immunosuppression. Based in San Francisco and launched in 2025, Ouro was founded by Monograph Capital in partnership with GSK. Ouro is also backed by leading investors TPG, NEA, and Norwest.
The financing was led by Sam Beavers, Joseph Jung Hyuk Yim, Will Ogden, Tucker Smith and Kingsley Taft and licensing was led by David Chen and Kelly Song. Additional assistance included Kevin Kabler and Pavel Puzerey; Daniel Karelitz and Katie Leah; and Justin Pierce, Jacob Osborn, and Gozde Guckaya.
For more information on the deal, please read the press release and coverage in Endpoints News.